1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 Jun 2024
Admin
News Article

Evolus Submits Premarket Approval Application to FDA for two Evolysse Dermal Filler Products

Overview

Evolus, Inc, a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced that it has submitted the final module of its premarket approval (PMA) application to the US Food and Drug Administration (FDA) for the Evolysse Lift and Evolysse smooth dermal filler products for the nasolabial fold (NLF).

Statement from R&D Expert

“We are pleased to have submitted the final module of the PMA application,” said Dr. Rui Avelar, MD, chief medical officer and head of R&D.
“This submission is a key fundamental milestone for Evolus and we look forward to our continued collaboration with the Agency in the upcoming thorough review process.”

Anticipated Approval: 2025

Evolus anticipates that the FDA’s review process will adhere to the standard timeline, with approval expected in the second half of 2025.
The submission underscores Evolus’ commitment to bringing the dermal filler products to market and its readiness to meet regulatory requirements.

Contents pf PMA Application

The PMA application includes results from the US pivotal study, which evaluated the safety and effectiveness of the products in a multicenter, blinded, split face, controlled, non-inferiority designed trial.
Patients were followed for 12 months from initial treatment.
A total of 140 patients were enrolled and divided evenly across two investigational arms.
Patients were randomized to receive Evolysse Lift or Evolysse Smooth in one NLF and Restylane-L in the contralateral NLF.
This split face design allowed each individual patient to experience one of the Evolysse fillers and the control at the same time.

Primary Endpoint

Both the Evolysse Lift and Evolysse smooth dermal filler products met their primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months.

Evolysse Lift Filler

The Evolysse Lift filler will be positioned as the most versatile for treating facial wrinkles and folds (such as NLFs) and is expected to be the highest use filler in the product line.
The Evolysse smooth filler will be positioned as an alternative softer formulation option to Evolysse Lift.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!